Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment
INTRODUCTION: Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairm...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293849/ https://www.ncbi.nlm.nih.gov/pubmed/35288777 http://dx.doi.org/10.1007/s00415-022-11055-5 |
_version_ | 1784749725518397440 |
---|---|
author | Giacomucci, Giulia Mazzeo, Salvatore Bagnoli, Silvia Ingannato, Assunta Leccese, Deborah Berti, Valentina Padiglioni, Sonia Galdo, Giulia Ferrari, Camilla Sorbi, Sandro Bessi, Valentina Nacmias, Benedetta |
author_facet | Giacomucci, Giulia Mazzeo, Salvatore Bagnoli, Silvia Ingannato, Assunta Leccese, Deborah Berti, Valentina Padiglioni, Sonia Galdo, Giulia Ferrari, Camilla Sorbi, Sandro Bessi, Valentina Nacmias, Benedetta |
author_sort | Giacomucci, Giulia |
collection | PubMed |
description | INTRODUCTION: Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores. MATERIALS AND METHODS: We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis. Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement. Patients were classified as A + if they presented at least one positive amyloid biomarker or A− if not. RESULTS: NfL levels were significantly increased in AD and MCI compared to SCD patients. These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A−. Similarly, MCI A + had higher NfL levels than MCI A−, but comparable with AD. NfL levels correlated with p-tau in SCD, with all CSF biomarkers in MCI patients. No correlations were found in AD subgroup. In SCD, NfL levels were negatively correlated with memory test scores. CONCLUSIONS: Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages. Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD. |
format | Online Article Text |
id | pubmed-9293849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-92938492022-07-20 Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment Giacomucci, Giulia Mazzeo, Salvatore Bagnoli, Silvia Ingannato, Assunta Leccese, Deborah Berti, Valentina Padiglioni, Sonia Galdo, Giulia Ferrari, Camilla Sorbi, Sandro Bessi, Valentina Nacmias, Benedetta J Neurol Original Communication INTRODUCTION: Neurofilament light chain (NfL) is becoming increasingly notable in neurological diseases including AD, and it has been suggested as a new peripherical biomarker of neurodegeneration. We aimed to compare plasma NfL levels among Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI), and AD patients and to evaluate relationships between NfL and CSF biomarkers and neuropsychological scores. MATERIALS AND METHODS: We enrolled 110 patients (34 SCD, 53 MCI, and 23 AD), who underwent clinical and neuropsychological evaluation, APOE genotyping, and plasma NfL analysis. Ninety-one patients underwent at least one amyloid burden biomarker (CSF and/or amyloid PET); 86 patients also underwent CSF phosphorylated-tau (p-tau) and total-tau (t-tau) measurement. Patients were classified as A + if they presented at least one positive amyloid biomarker or A− if not. RESULTS: NfL levels were significantly increased in AD and MCI compared to SCD patients. These differences depend on A status, e.g., SCD A + had lower NfLs than MCI A + but comparable with MCI A−. Similarly, MCI A + had higher NfL levels than MCI A−, but comparable with AD. NfL levels correlated with p-tau in SCD, with all CSF biomarkers in MCI patients. No correlations were found in AD subgroup. In SCD, NfL levels were negatively correlated with memory test scores. CONCLUSIONS: Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages. Considering correlations with CSF p-tau and memory tests in SCD, NfL might be a useful peripheral biomarker also in preclinical phases of AD. Springer Berlin Heidelberg 2022-03-14 2022 /pmc/articles/PMC9293849/ /pubmed/35288777 http://dx.doi.org/10.1007/s00415-022-11055-5 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Giacomucci, Giulia Mazzeo, Salvatore Bagnoli, Silvia Ingannato, Assunta Leccese, Deborah Berti, Valentina Padiglioni, Sonia Galdo, Giulia Ferrari, Camilla Sorbi, Sandro Bessi, Valentina Nacmias, Benedetta Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment |
title | Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment |
title_full | Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment |
title_fullStr | Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment |
title_full_unstemmed | Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment |
title_short | Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in Subjective Cognitive Decline and Mild Cognitive Impairment |
title_sort | plasma neurofilament light chain as a biomarker of alzheimer’s disease in subjective cognitive decline and mild cognitive impairment |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293849/ https://www.ncbi.nlm.nih.gov/pubmed/35288777 http://dx.doi.org/10.1007/s00415-022-11055-5 |
work_keys_str_mv | AT giacomuccigiulia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT mazzeosalvatore plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT bagnolisilvia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT ingannatoassunta plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT leccesedeborah plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT bertivalentina plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT padiglionisonia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT galdogiulia plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT ferraricamilla plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT sorbisandro plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT bessivalentina plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment AT nacmiasbenedetta plasmaneurofilamentlightchainasabiomarkerofalzheimersdiseaseinsubjectivecognitivedeclineandmildcognitiveimpairment |